Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Novartis Pharmaceuticals

31 clinical trials · 31 recruiting · INDUSTRY

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by Novartis Pharmaceuticals

RECRUITINGNCT07243002

Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.

This non-interventional study (NIS) aims to evaluate effectiveness, persistence, treatment patterns, adverse events (AEs), and patient-reported experience (including adherence,...

Sponsor: Novartis PharmaceuticalsEnrolling: 30001 location
Breast Cancer
RECRUITINGPhase 1 / Phase 2NCT07226986

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI...

The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium (177Lu)...

Sponsor: Novartis PharmaceuticalsEnrolling: 1236 locations
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
RECRUITINGPhase 1 / Phase 2NCT07206056

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462...

This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide)...

Sponsor: Novartis PharmaceuticalsEnrolling: 18820 locations
Progressive Metastatic Castrate Resistant Prostate Cancer
RECRUITINGPhase 1 / Phase 2NCT04104776

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients...

Sponsor: Novartis PharmaceuticalsEnrolling: 27520 locations
Advanced Solid TumorDiffuse Large B Cell LymphomaLymphoma, T-Cell+5
RECRUITINGPhase 1 / Phase 2NCT06617793

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

This is an open-label, multi-center, non-confirmatory study to assess the safety, efficacy, and cellular kinetics of YTB323 in approximately 28 participants with Relapsing...

Sponsor: Novartis PharmaceuticalsEnrolling: 2818 locations
Relapsing Multiple Sclerosis
RECRUITINGPhase 3NCT07326709

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease...

Sponsor: Novartis PharmaceuticalsEnrolling: 7702 locations
Huntington Disease
RECRUITINGPhase 2NCT07217067

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial...

A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden as well as the safety, tolerability...

Sponsor: Novartis PharmaceuticalsEnrolling: 16520 locations
Atrial Fibrillation
RECRUITINGPhase 1 / Phase 2NCT06649110

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)

Sponsor: Novartis PharmaceuticalsEnrolling: 23220 locations
Healthy Volunteers, Pulmonary Arterial Hypertension
RECRUITINGPhase 3NCT06597006

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial...

This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to \<12 years) with homozygous familial...

Sponsor: Novartis PharmaceuticalsEnrolling: 918 locations
Familial Hypercholesterolemia - Homozygous
RECRUITINGPhase 1 / Phase 2NCT07048197

A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis...

A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren's disease

Sponsor: Novartis PharmaceuticalsEnrolling: 2711 locations
Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
RECRUITINGPhase 1NCT07029555

An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis

The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565, in participants with rheumatoid arthritis (RA).

Sponsor: Novartis PharmaceuticalsEnrolling: 5713 locations
Rheumatoid Arthritis
RECRUITINGPhase 3NCT06133972

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus...

The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the...

Sponsor: Novartis PharmaceuticalsEnrolling: 55020 locations
Systemic Lupus Erythematosus
RECRUITINGPhase 2NCT05268289

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

Sponsor: Novartis PharmaceuticalsEnrolling: 24020 locations
Lupus Nephritis
RECRUITINGPhase 3NCT06711887

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in...

The purpose of this 2-year extension study is the evaluation of the efficacy and safety 1. after study treatment withdrawal in patients with lupus nephritis (LN) who achieved...

Sponsor: Novartis PharmaceuticalsEnrolling: 31520 locations
Lupus Nephritis
RECRUITINGPhase 2NCT06581198

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN)...

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory...

Sponsor: Novartis PharmaceuticalsEnrolling: 17920 locations
Lupus Erythematosus, SystemicLupus Nephritis
RECRUITINGNCT06382051

Modifying PEST for Psoriatic Arthritis Screening

The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with...

Sponsor: Novartis PharmaceuticalsEnrolling: 50215 locations
Plaque PsoriasisPsoriatic Arthritis
RECRUITINGPhase 1 / Phase 2NCT06704269

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a...

Sponsor: Novartis PharmaceuticalsEnrolling: 1510 locations
Generalized Myasthenia Gravis
RECRUITINGPhase 3NCT06517758

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants...

The study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG...

Sponsor: Novartis PharmaceuticalsEnrolling: 14620 locations
Generalized Myasthenia Gravis
RECRUITINGPhase 3NCT06744920

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With...

A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care...

Sponsor: Novartis PharmaceuticalsEnrolling: 18020 locations
Generalized Myasthenia Gravis
RECRUITINGPhase 2NCT06868290

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis...

Sponsor: Novartis PharmaceuticalsEnrolling: 12620 locations
ANCA Associated Vasculitis (AAV)
RECRUITINGNCT06838143

Ilaris NIS in Korea

This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications,...

Sponsor: Novartis PharmaceuticalsEnrolling: 251 location
Hereditary Periodic Fever SyndromesCryopyrin-associated Periodic Syndromes (CAPS)Colchicine Resistance Familial Mediterranean Fever (crFMF)+3
RECRUITINGPhase 3NCT07102628

Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute...

The purpose of this trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early...

Sponsor: Novartis PharmaceuticalsEnrolling: 30020 locations
Acute Coronary Syndrome
RECRUITINGPhase 4NCT06501443

LATAM LOWERS LDL-C

This is an open label, patient-level 1:1 randomized clinical trial in a multi-country study aiming to evaluate the real-world impact of inclisiran + Usual Care (UC) vs UC alone on...

Sponsor: Novartis PharmaceuticalsEnrolling: 52011 locations
Hypercholesterolaemia
RECRUITINGPhase 2NCT07235046

A Study of DII235 in Adults With Elevated Lipoprotein(a)

The main purpose of this study is to determine the safety and efficacy of DII235 in adults with elevated lipoprotein(a).

Sponsor: Novartis PharmaceuticalsEnrolling: 20020 locations
Lipoprotein Disorder
RECRUITINGPhase 3NCT05562466

A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in...

The purpose of this study is to evaluate the superiority in terms of efficacy and evaluate the safety of QMF149 (indacaterol (acetate) / mometasone (furoate)) compared to...

Sponsor: Novartis PharmaceuticalsEnrolling: 20020 locations
Asthma
RECRUITINGPhase 2NCT05750628

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium...

Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria

Sponsor: Novartis PharmaceuticalsEnrolling: 32712 locations
Uncomplicated Plasmodium Falciparum Malaria
RECRUITINGNCT06019637

A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With Zolgensma

A long-term safety study in Brazilian patients with a confirmed diagnosis of Spinal Muscular Atrophy (SMA) treated with Onasemnogene Abeparvovec (Zolgensma®)

Sponsor: Novartis PharmaceuticalsEnrolling: 502 locations
Spinal Muscular Atrophies
RECRUITINGPhase 3NCT05335876

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials

This is a global, prospective, multi-center study that is designed to assess the long-term safety and efficacy of OAV101 in patients who participated in an OAV101 clinical trial....

Sponsor: Novartis PharmaceuticalsEnrolling: 17520 locations
Spinal Muscular Atrophy (SMA)
RECRUITINGPhase 1 / Phase 2NCT07190300

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and...

The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or...

Sponsor: Novartis PharmaceuticalsEnrolling: 15520 locations
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
RECRUITINGNCT04174157

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN...

Sponsor: Novartis PharmaceuticalsEnrolling: 70020 locations
Spinal Muscular Atrophy (SMA)

Showing 30 of 31 trials.